Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statins: is it really time to reassess benefits and risks?

× No keyword cloud information.

33 in total

Review 1. Is immunity a mechanism contributing to statin-induced diabetes?

Authors: Brandyn D Henriksbo; Jonathan D Schertzer
Journal: Adipocyte Date: 2015-04-20 Impact factor: 4.534

2. Epidemiology and long-term clinical and biologic risk factors for pneumonia in community-dwelling older Americans: analysis of three cohorts.

Authors: Sachin Yende; Karina Alvarez; Laura Loehr; Aaron R Folsom; Anne B Newman; Lisa A Weissfeld; Richard G Wunderink; Stephen B Kritchevsky; Kenneth J Mukamal; Stephanie J London; Tamara B Harris; Doug C Bauer; Derek C Angus
Journal: Chest Date: 2013-09 Impact factor: 9.410

Review 3. Differential metabolic actions of specific statins: clinical and therapeutic considerations.

Authors: Soo Lim; Ichiro Sakuma; Michael J Quon; Kwang Kon Koh
Journal: Antioxid Redox Signal Date: 2013-09-24 Impact factor: 8.401

Review 4. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Authors: Allison B Goldfine; Steven E Shoelson
Journal: J Clin Invest Date: 2017-01-03 Impact factor: 14.808

Review 5. The evolution or revolution of statin therapy in primary prevention: where do we go from here?

Authors: Patricia Rehfield; Colin Kopes-Kerr; Michael Clearfield
Journal: Curr Atheroscler Rep Date: 2013-02 Impact factor: 5.113

Review 6. The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?

Authors: Michael Clearfield; Melissa Pearce; Yasmin Nibbe; David Crotty; Alesia Wagner
Journal: Curr Atheroscler Rep Date: 2014-01 Impact factor: 5.113

Statins: is it really time to reassess benefits and risks?

Review 1. Is immunity a mechanism contributing to statin-induced diabetes?

2. Epidemiology and long-term clinical and biologic risk factors for pneumonia in community-dwelling older Americans: analysis of three cohorts.

Review 3. Differential metabolic actions of specific statins: clinical and therapeutic considerations.

Review 4. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Review 5. The evolution or revolution of statin therapy in primary prevention: where do we go from here?

Review 6. The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?

7. Inadequacies of current approaches to prediabetes and diabetes prevention.

Review 8. FDA drug safety communications: a narrative review and clinical considerations for older adults.

9. Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Review 10. Statin use in prediabetic patients: rationale and results to date.